Ke halaman utama

Halaman 3 - Konsultasi Daring dengan Dokter Onkologi Dokter Terbaik - TOP-73 dokter

Konten memenuhi Kebijakan Editorial Bookimed dan ditinjau secara medis oleh

Fahad Mawlood

Prof. Sezer Sağlam

  • 5 Sangat baik 1 ulasan
  • 27 tahun pengalaman
  • Turquia, Istambul, Gayrettepe Florence Nightingale Hospital
  • Personal Information 

    Sex:  Male

    Born : 1968 

     

    Professional Experience

    Gayrettepe Florence Nigthingale Hospital

    Medical Oncology Department

    Besiktas/Istanbul/Turkey (ongoing)

     

    Education:

    He became Professor (22/April /2016)

    Medical Oncology

     

    Attending Phys.in Gastrointestinal Oncology (January 2005 ,2009)

    Istanbul University Oncology Institue,

    Department of Medical Oncology

     

    Medical Oncology Fellowship (December 2001-December2004)

    Istanbul University, Istanbul Medical Faculty

     

    Hemodialysis Traning (May1996-January1997)

    Istanbul University ,bCerrahpasa Medical Faculty

     

    Internal Medicine Residency (November 1991-November 1996)

    Istanbul University ,bCerrahpasa Medical Faculty

     

    Ege University Medical Faculty (1985-1991)

     

    Professional Experience

    February 1999-November 2001

    Metropolitan Florence Nigthingale Hospital

    American Cancer Center, Gayrettepe/İstanbul

     

    April1997- October 1998

    Bayraktar Dialysis Center

    Güngören/ Istanbul

     

    Membership

    Turkish Medical Oncology Association

    ENET(European Neuroendocrine Tumour Society)

    ESMO

    ASCO

  • Baca selengkapnya
Kunjungan dokter
Harga berdasarkan permintaan
Info

Ari Raphael

  • 4.5 Baik 153 ulasan
  • 29 tahun pengalaman
  • akreditasi:
  • Israel, Telavive, Sourasky Medical Center (Ichilov)
  • Profesor Ari Rafael — direktur layanan Onkologi Translasional dan peneliti di departemen penelitian klinis kanker di Pusat Medis Suraski (Ichilov, Tel Aviv). Pasien menghargai pendekatannya yang individual dan perhatian terhadap kebutuhan setiap individu.

    Kualifikasi dan nilai bagi pasien:

    • Memimpin rumah sakit onkologi siang hari dan mengarahkan proyek-proyek kedokteran genom nasional. Hal ini memastikan akses ke penelitian terkini.

    • Bekerja sebagai penyelidik sub-utama dan penyelidik utama dalam banyak uji klinis fase I–III, termasuk suntikan intratumoral mRNA dan obat-obatan virus. Pasien mendapatkan kesempatan untuk berpartisipasi dalam metode pengobatan inovatif.

    • Memiliki pengalaman internasional di AS dan Inggris — menjamin penerapan standar dunia dan protokol canggih.

    • Anggota organisasi internasional (ESMO, IASLC, ISLB, ISCORT, Asosiasi Medis Israel). Menggunakan standar pengobatan modern dan berpartisipasi dalam penelitian global.

    • Secara rutin meningkatkan kualifikasi dan mengikuti pelatihan sesuai standar praktik klinis internasional, termasuk ICH GCP R2, Panduan MOH Israel, serta kursus terbaru tentang persetujuan yang diinformasikan, penanganan efek samping, dan keselamatan pasien.

    Pasien menghargai Profesor Rafael atas pilihan rencana pengobatan yang tepat, penerapan inovasi, dan perhatian yang mendetail, yang memberikan rasa percaya dan aman pada setiap tahap terapi.

  • Baca selengkapnya
Info

Muhammed Gomec

  • 5 Sangat baik 1 ulasan
  • 17 tahun pengalaman
  • Turquia, Sivas, Medicana Sivas Hospital
Kunjungan dokter
Harga berdasarkan permintaan
Info

Hamza Ugur Bozbey

  • Baru
  • 12 tahun pengalaman
  • Turquia, Istambul, Uniqacare Clinic
Kunjungan dokter
Harga berdasarkan permintaan
Info

Hilmi Apak

  • Baru
  • 26 tahun pengalaman
  • Turquia, Istambul, Biruni University Hospital
  • Dr. Hilmi Apak is a respected pediatric hematology-oncology specialist with more than 21 years of experience. He is trained in pediatric oncology. Dr. Apak has led advanced treatments, including bone marrow transplantation, leukemia chemotherapy, and CAR T-cell therapy.

    He has published 75 international medical articles, showing his strong contribution to pediatric oncology research. Dr. Apak has worked as assistant editor for the Turkish Pediatrics Archives Periodical. He has also held important academic and leadership positions, such as Head of Pediatric Hematology-Oncology at Istanbul University-Cerrahpaşa.

  • Baca selengkapnya
Brahiterapi
$10,000 - $12,000
Tomoterapi
$8,440 - $14,140
Info

Abdullah Sakin

  • 4.5 Baik 2 ulasan
  • 19 tahun pengalaman
  • Turquia, Istambul, Medipol Bahçelievler Hospital
  •  

    Experience

    2022 PRIVATE MEDIPOL BAHÇELİEVLER HOSPITAL

     

    2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital, Medical Oncology Clinic Education Officer

     

    2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital

     

    2020 - 2021 Yüzüncü Yıl University Faculty of Medicine

     

    2020 - 2021 Head of the Department of Medical Oncology, Yüzüncü Yıl University Faculty of Medicine, Assoc. Dr.  

     

    2018 - 2021 Lecturer - Yüzüncü Yıl University Faculty of Medicine, Head of Medical Oncology Department  

     

    2018 - 2021 Yüzüncü Yıl University Faculty of Medicine

     

    2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital

     

    2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital, Medical Oncology Clinic, Sub-branch assistant

     

    2012 - 2015 Kanuni Sultan Süleyman Training and Research Hospital, Internal Medicine specialist

     

    2012 - 2015 Suleiman the Magnificent Training and Research Hospital,

     

    2008 - 2012 Haseki Training and Research Hospital

     

    2006 - 2008 Kızıltepe No. 3 Health Center General Practitioner.

     

     

    Education

    2018

    İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

    2018

    İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji, İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

    2012

    İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları, İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

    2012

    İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

    2007

    Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi, Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi

     

  • Baca selengkapnya
Radioterapi untuk kanker rahim
$4,000 - $6,000
Operasi Whipple
$18,000 - $25,000
Tiroidektomi
$4,000 - $5,500
Info

Nail Paksoy

  • 4.5 Baik 2 ulasan
  • 15 tahun pengalaman
  • akreditasi:
  • Turquia, Istambul, Medipol Bahçelievler Hospital

  • PROFESSIONAL EXPERIENCE

    2011-2012
    Erzurum Koprukoyu State Hospital
    Department: General Medicine

    2012-2017
    Istanbul University Cerrahpaşa Medical Faculty
    Department: Internal Medicine

    06/2017-10/2017
    Istanbul Gaziosmanpasa Taksim Training and Research Hospital
    Department: Internal Medicine

    10/2017-11/2018
    Istanbul University Istanbul Medical Faculty
    Department: Allergy and Immunology Fellowship

    2018/2022
    Istanbul University Oncology Institute
    Department: Medical Oncology Fellowship

    2022-2023
    Tekirdag City Hospital
    Department: Medical Oncology Specialist

    2023-present
    Istanbul Medipol University Medipol Bahcelievler Private Hospital
    Department: Medical Oncology Assoc. Prof.

     

    EDUCATION

    2005-2011
    Medical Education
    Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

    2012-2017
    Internal Medicine
    Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

    2017-2018
    Allergy-Immunology Fellowship
    Istanbul University Istanbul Medical Faculty
    Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

    2018-2022
    Medical Oncology Fellowship
    Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

    2022
    ESMO Board Certification in Medical Oncology
    10th September 2022 in Paris, France.

    2023
    Medical Oncology Assoc. Prof.
    Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

     

    INTERNATIONAL CLINICAL TRIALS:

    1. Astefania - ROCHE

    • Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
    • Role: Subinvestigator

    2. PFİZER

    • Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
    • Role: Subinvestigator

    3. RECITE - AMGEN

    • Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
    • Role: Subinvestigator

    4. NAVIGATE - BAYER

    • Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
    • Role: Subinvestigator

    5. RUBY - Tesaro (PRA)

    • Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
    • Role: Subinvestigator

    6. ENGOT-ov43/GOG-3036 - MSD

    • Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
    • Role: Subinvestigator

    7. ASTRA ZENECA

    • Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
    • Role: Subinvestigator

    8. ROSY-O - ASTRA ZENECA

    • Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
    • Role: Subinvestigator
    •  

    INTERNATIONAL PUBLICATIONS

    I. Published journal articles indexed by SCI, SSCI, and AHCI

    Weekly Paclitaxel in Classic Kaposi Sarcoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
    • Journal: Medicine, 102(5)

    Carboplatin Desensitization in Ovarian Carcinoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
    • Journal: Medicine, 101(45), e31726

    High-Dose Chemotherapy for Ewing’s Sarcoma

    • Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
    • Journal: Medicine, 101(49), e32213

    Multidrug Refractory TFE3(+) Renal Cell Carcinoma

    • Authors: Paksoy, Nail, et al.
    • Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

    Crizotinib Efficacy in NSCLC with MET Alterations

    • Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
    • Journal: Medicine, 101(50), e32368

    Clinicopathological Features in ALK Mutant NSCLC

    • Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
    • Journal: Medicine, 101(34)

    PSMA-Based Tumor Burden in Prostate Cancer

    • Authors: HAS SIMSEK, Duygu, et al.
    • Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

    Atezolizumab in Metastatic Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: European Urology Focus, 2021, 7.5: 1061-1066

    Pulmonary Sarcomatoid Carcinoma

    • Authors: FERHATOGLU, Ferhat, et al.
    • Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

    Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

    Atezolizumab with Chemotherapy in Small Cell Lung Cancer

    • Authors: GÜRBÜZ, Mustafa, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

    FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

    • Authors: AY, Seval, et al.
    • Journal: Journal of Chemotherapy, 2022, 1-7

    Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

    • Authors: CIL, Ibrahim, et al.
    • Journal: Tumori Journal, 2022, 108.1: 19-25

    Real-Life Efficacy of Osimertinib in Advanced NSCLC

    • Authors: HIZAL, Mutlu, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

    ALK-Positive Cells Percentage and Alectinib Efficacy

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
    • Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

    Real-World Data on Alectinib in ALK-Positive NSCLC

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
    • Journal: Future Oncology, 18(23), 2573-2582

    Prognostic Factors in Metastatic RCC with T790M Mutation

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

    • Authors: DEMIR, Semra, et al.
    • Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

    Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

    • Authors: ÖZDEMIR, Seçil Kepil, et al.
    • Journal: Allergy, 2019, 74.6: 1187-1190

    Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

    • Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
    • Journal: The Oncologist, oyad257

    Subsequent Treatments in Hormone-Positive Breast Cancer Progression

    • Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
    • Journal: BMC cancer, 23(1), 192

    Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
    • Journal: Scientific Reports, 13(1), 8779

    Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
    • Journal: Journal of Cancer Research and Clinical Oncology, 1-9

    Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

    • Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
    • Journal: European Journal of Breast Health, 19(2), 128

    Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

    • Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
    • Journal: Future Oncology, 19(10), 727-736

    Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

    • Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
    • Journal: [Not specified]

    Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

    • Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
    • Journal: Medicine, 102(39), e35383

    Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

    • Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
    • Journal: Medicine, 102(41), e35245

    Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

    Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

    Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

    Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

    Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

    Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

    Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

    Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

    Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

    Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

    Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

    Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

    Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

     

    Thesis:

    Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

    International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

    Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

    • Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

    Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

    • Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

    Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

    • Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

    Efficacy of temozolomide in pretreated patients with metastatic sarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

    • Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

    • Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

    Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

    • Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

    Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

    • Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

    Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

    • Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

     

     

  • Baca selengkapnya
Radioterapi untuk kanker rahim
$4,000 - $6,000
Operasi Whipple
$18,000 - $25,000
Tiroidektomi
$4,000 - $5,500
Info

Francesc Cobo Valien

  • 4.7 Sangat baik 435 ulasan
  • 27 tahun pengalaman
  • Espanha, Barcelona, Centro Médico Teknon
  • Dr. Francesc Cobo Valien graduated from the Faculty of Medicine of the University of Barcelona in 1990.

    He received his specialization in oncohematology at the Hospital Clínic de Barcelona in 1995. He combined medical practice and research activities in the period 1996-2002.

    He received his Doctor of Medicine degree from the University of Barcelona in 2002.

    Dr. Kobo continues his research and has been awarded grants:

    •Interdepartmental Commission for Innovation of the Generalitat de Catalunya

    •Scholarship Fund Universitaria Agustí Pedro i Pons

    •Farreras Valentí & Schering Plough School of Hematology Scholarship

    •Award for the best report at the Council of the Spanish Hematology Association

    •Grant from the Catalan Society of Hematology

    Specialization:

    •Lymphoma

    •Acute leukemia

    •Chronic leukemia

    •Autoimmune pancytopenia

  • Baca selengkapnya
Imunoterapi
$4,000 - $5,000
Operasi kanker payudara
$19,728.31 - $29,012.23
Nefrektomi
$19,728.31 - $23,209.78
Info

Carme Balana Quintero

  • 4.7 Sangat baik 435 ulasan
  • 25 tahun pengalaman
  • Espanha, Barcelona, Centro Médico Teknon
  • Dr. Balaña received her medical degree from the Central University of Barcelona and completed her residency in medical oncology at one of the best public hospitals in Spain, Vall d'Hebrón Hospital.

    She was a leading specialist in the treatment of brain tumors at the Institute of Oncology of Catalonia, a founding member and current president of the Spanish Neuro oncology Research Group (GEINO), and a member of the scientific committee of the European Association for Neuro-Oncology.

    He is the recipient of prestigious research grants in the field of brain tumors.

    Dr. Balaña is also a member of the European Society of Medical Oncology and the author of modern European protocols for the treatment of brain tumors, as well as the protocols of the Spanish Society of Medical Oncology (SEOM).

    Dr. Balaña has published over 400 articles, books and scientific papers at national and international conferences.

    He is the author of articles in prestigious scientific publications such as:

    Lancet Oncology;

    Nature Reviews in Clinical Oncology;

    Clinical Cancer Research and others.

  • Baca selengkapnya
Imunoterapi
$4,000 - $5,000
Operasi kanker payudara
$19,728.31 - $29,012.23
Nefrektomi
$19,728.31 - $23,209.78
Info

Sefik Igdem

  • 5 Sangat baik 1 ulasan
  • 30 tahun pengalaman
  • Turquia, Istambul, Gayrettepe Florence Nightingale Hospital
  • Personal information

    Title: Professor Doctor

    Branch: Radiation Oncology

    Work History:

    1 GATA Military Medical Faculty

    2 Gayrettepe Florence Nightingale Hospital

    3 T.R. Demiroğlu Bilim University \ Associate Professor

    4 T.R Demiroğlu Bilim University \ Professor

    Medical Specialties and Subspecialties:

    1 Head and Neck Cancers

    2 Radiation Oncology

    Priority treatments:

    1 Prostate cancer

    2 Conformal treatments

    Special advanced health technologies:

    1 Truebeam Stx Technology

    2 Halcyons

    Education

    1991 - Istanbul University Istanbul Faculty of Medicine

    1996 - Istanbul University Cerrahpaşa Faculty of Medicine Radiation

    Oncology Specialization Training

     

  • Baca selengkapnya
Kunjungan dokter
Harga berdasarkan permintaan
Info

Ohm Sudchumphae

  • 5 Sangat baik 2 ulasan
  • 14 tahun pengalaman
  • Tailândia, Banguecoque, Panacee Hospital Rama2 - Regenerative Hub
  • 1.Bachelor’s degree
    - Doctor of medicine, Rangsit university.

    2.Master’s degree

    >Medical and health science degree
    - Professional master’s degree in clinical nutrition in medicine.
    - Professional master’s degree in integrative medicine.

    >Management degree
    - Professional master’s degree in hospital and health services management.

    3.Doctorate degree
    - Doctorate in psychology (candidate).

    4.Diploma
    - American Bord of nutritional wellness.
    - American naturopathic certification board.

    - Certified integrative oncology physician, American institute of integrative oncology.

    - Certified fertility wellness physician.

    - Certified CBT-I physician.

    - Advanced nutritional wellness, IFNW.

    -Biochemical and clinical analysis diploma.

    - Functional gastroenterology and pediatric food allergies diploma.

    - IV nutrition diploma, IFNW.

    -Medicinal herbology diploma, IFNW.

  • Baca selengkapnya
Kemoterapi
$1,000 - $3,000
Terapi target
$1,000 - $3,000
Info

Constantinos Zamboglou

  • Baru
  • 13 tahun pengalaman
  • Chipre, República de Chipre, German Medical Institute (GMI)
  • Education

    09 / 2004 – 07 / 2006                Movie Director School, ANT1 Movie School Athens, Greece, Degree “Television Director”, grade point average: B

    09 / 2006 – 08 / 2008                Medical School, Semmelweis University Budapest, Hungary, Medical preliminary examination (Physikum), grade point average: A

    10 / 2008 – 05 / 2013                Medical School, Albert-Ludwigs-Universität Freiburg, Germany, State examination in medicine, grade point average: A

    02/ 2009 – 02/2012                   Institute of Pharamcology and Toxicology I, Albert-Ludwigs-Universität Freiburg, GermanyDoctoral thesis, grade: summa cum laude

    05 / 2018                                      Basic and advanced course in German drug law and GCP, Clinical Trials Unit, Medical Center - University of Freiburg

    01 / 2019                                      Board certification: Radiotherapy and Radiation Oncology

    03 / 2020                                      Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Habilitation (Postdoctoral lecture qualification)

    09 / 21 – 08 / 23                         MHBA, Friedrich Alexander University, Nuernberg, Germany

    07 / 2022                                      Completion of ISO 9001:2015 training, Nicosia, Cyprus

    Professional Career

    09 / 2013 – 01 / 2019               Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Residency                                                

    07 / 2017 – 07 / 2020               Bertha-Ottenstein programme, Medical Center, University of Freiburg, Germany, Clinician Scientist

    Since 06 / 2019                          Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Consultant

    01 / 2021 – 12 / 2022                Bertha-Ottenstein programme, Medical Center, University of Freiburg, Germany, Advanced Clinician Scientist

    01 / 2021 – 12 / 2021                 Head of the section “Interventional Radiation Oncology”, Medical Center University of Freiburg, Department of Radiation Oncology, Germany

    Since 01 / 2022                         Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Prostate cancer research group leader

    Since 01 / 2022                          German Medical Institute, Limassol, Cyprus, Vice Medical Director

    Professional Memberships and Distinctions

    2010           Sanofi-Aventis poster prize, Annual meeting of the German Society of Pharmacology and Toxicology 2010, Mainz, Germany      

    2017           Poster prize, Annual meeting of the German Society of Radiation Oncology (DEGRO) 2017, Berlin, Germany

    2019           Poster prize, Uro-Oncological Symposium 2019, Magdeburg, Germany

    2020           Invited member of the German expert panel for prostate cancer of the German Society of Radiation Oncology (DEGRO)

    2020           Herman-Holthusen Award, German Society of Radiation Oncology (DEGRO)

    2021           Invited member of the ESTRO-ACROP guideline committee for prostate cancer

    2021           Best Abstract, EMUC congress 2021, Athens, Greece

    2023           Annual ARO study price for the HypoFocal-SBRT study from the German Cancer Foundation

    2023           Invited member of the ESTRO focus group “Urology”

  • Baca selengkapnya
Kunjungan dokter
Harga berdasarkan permintaan
Info

Konstantinos Ferentinos

  • Baru
  • 13 tahun pengalaman
  • Chipre, República de Chipre, German Medical Institute (GMI)
    • Education: 
    •  
    • 2001-2007: University of Ioannina Medical School, Greece.
    • 2007: Degree in Medicine.
    • 2013: Doctoral degree from the Medical School of the Johann Wolfgang Goethe University, Frankfurt (Dr. Med)
    • 09.2016 – Today: Master’s in Healthcare Business Studies.

    Professional experience:

    04.2009 – 04.2013: Resident in the Department for Radiation Oncology, Klinikum Offenbach

    05.2013 – 12. 2015: Senior physician in the Department for Radiation Oncology, Klinikum Offenbach

    • 01.2016 – 06.2017: Senior physician in the Department of interventional Radiation Oncology, Medical Center Athens
    •  
    • 07.2017 – Today: Head of the Department of Radiation Oncology at the German Oncology Center, Limassol, Cyprus.
  • Baca selengkapnya
Kunjungan dokter
Harga berdasarkan permintaan
Info

Havva Asuman Yavuz

  • 4.5 Baik 6 ulasan
  • 28 tahun pengalaman
  • Turquia, Antália, Medical Park Antalya Hospital Complex
  • Education and Specialization

    • Hacettepe University Faculty of Medicine – English Medical Education
    • Akdeniz University Faculty of Medicine – Internal Medicine – Residency
    • Akdeniz University Hospital – Nephrology – Subspecialty Training
    • San Bortolo Hospital, Vicenza, Italy – Critical Care Nephrology and Transplantation – Fellowship
    • Hacettepe University Faculty of Medicine – Associate Professorship

    Professional Memberships

    1. Turkish Society of Nephrology (TND)
    2. European Society of Nephrology (ERA-EDTA)
    3. Middle East Society of Organ Transplantation (MESOT)
    4. International Society of Nephrology (ISN)
  • Baca selengkapnya
Reseksi tiroid
$7,500 - $7,500
Mastektomi
$7,500 - $7,500
Info

Cemil Bilir

  • 5 Sangat baik 1 ulasan
  • 21 tahun pengalaman
  • Turquia, Istambul, VM Medical Park Pendik Hospital
  • Education & Expertise

    • 1998 to 2004 – Istanbul University, Istanbul Faculty of Medicine
    • 2005 to 2009 – Düzce University, Internal Medicine Specialization
    • 2009 to 2010 – Beytüşşebap State Hospital, Compulsory Internal Medicine Service
    • 2010 to 2013 – Bülent Ecevit University, Medical Oncology Specialization
    • 2013 to 2015 – Recep Tayyip Erdoğan University, Medical Oncology Compulsory Service
    • 2015 to Present – Associate Professor, Recep Tayyip Erdoğan University
    • 2015 to 2021 – Lecturer, Medical Oncology, Sakarya University Faculty of Medicine
    • 2020 to Present – Professor, Sakarya University Faculty of Medicine
    • 2020 to Present – Ph.D. Student, Inorganic Chemistry, Sakarya University

    Experience

    • 2008 – Cleveland Clinic, Rheumatology & Gastroenterology Rotation
    • 2016 to 2017 – Northeastern University, The Center for Pharmaceutical Biotechnology and Nanomedicine, Boston, U.S.

    Professional Memberships

    • TTOD (Turkish Society of Medical Oncology)
    • ASCO (American Society of Clinical Oncology)
    • ESMO (European Society for Medical Oncology)
  • Baca selengkapnya
Pengangkatan tumor otak
$12,000 - $15,000
Mastektomi
$6,500 - $8,000
Info

Erel Joffe

  • 4.5 Baik 153 ulasan
  • 36 tahun pengalaman
  • Israel, Telavive, Sourasky Medical Center (Ichilov)
Info

Erkancakir

  • 5 Sangat baik 7 ulasan
  • 36 tahun pengalaman
  • Turquia, Istambul, Liv Hospital Vadistanbul
  • Dr. Erkancakir is a specialist in pediatric chest diseases. He has experience with acute and chronic respiratory problems, respiratory tract infections, and bronchoscopic procedures. His areas of focus include asthma, sleep-related breathing disorders, cystic fibrosis, and tuberculosis.

    He completed his medical degree at Istanbul University. He continued his specialty training at Göztepe Training and Research Hospital and Marmara University. Dr. Erkancakir has worked at leading institutions, such as Bezmialem Vakıf University and Süreyyapaşa Chest Diseases Training and Research Hospital.

    He is an active member of several professional organizations, including the Turkish Thoracic Society and the European Respiratory Society. Dr. Erkancakir has received more than 20 national and international awards for his research and presentations, especially in pediatric pulmonology and cystic fibrosis.

  • Baca selengkapnya
Kemoterapi
$3,000 - $3,500
Info

Emre Merdan Fayda

  • 5 Sangat baik 7 ulasan
  • 46 tahun pengalaman
  • Turquia, Istambul, Liv Hospital Vadistanbul
  • Areas of Interests

    • MR Linac
    • Three Dimensional Brachytherapy
    • Four Dimensional (4D) Radiotherapy
    • Stereotactic RT & IMRT
    • Breast Cancer, Gynecological Cancers
    • Head – Neck Cancers
    • Urological Tumors, Gastrointestinal Cancers
    • Lung Cancer
    • Central Nervous System Tumors & Metastases
    • Skin Cancers
    • Soft Tissue Tumors

    Education:

    • Istinye University Medical Faculty, Professor Doctor (2017 – Continued)
    • Istine University Medical Faculty Associate Professor Doctor (2016 – 2017)
    • Liv Hospital Radiation Medicine Center, Tbilisi, Georgia, Radiation Oncology Consulting Docor (2016 – 2019)
    • Liv Hospital, Radiation Oncology (2015 – Continued)
    • Istanbul University Oncology Institution, Associate Professor (2012 – 2015)
    • Stereotactic Radiotherapy, Thoracic Oncology, University of North Carolina, NC, USA (2010 – 2011)
    • Kocaeli University Radiation Oncology Department, Associate Professor Assistant (2006 – 2009)
    • GATA Radiation Oncology Department, Specialist Doctor, Reserve Officer (2004 – 2005)
    • Istanbul University, Medical Faculty, Dr.R.A. (1999 – 2004)
    • Istanbul University, Medical Faculty, Under-Graduate (1993 – 1999)
       

    Experience:

    • Istinye University Medical Faculty
    • Liv Hospital Ulus
    • Istanbul University Oncology Institution
    • University of North Carolina, NC, USA
    • Kocaeli University Medical Faculty
    • Istanbul University, Medical Faculty
  • Baca selengkapnya
Kemoterapi
$3,000 - $3,500
Info

Brenda Pastrana

  • Baru
  • 6 tahun pengalaman
  • México, Cancún, Galenia Hospital
  • Doctor Brenda Pastrana is a mexican surgical Oncologist. 

    Medical background.

    Centro Medico Nacional 20 de Noviembre Issste, Surgical Oncologist in 2020.

    Title by Universidad Autónoma de México UNAM.

    Surgical Residency Instituto Mexicano del Seguro Social. 2015.

    Title by Universidad de Quintana Roo. 

    Board Certified by Conacem from 2020 to 2025 number 2171 

    Board Certified by Conacem from 2025 to 2030 number 2171

    Member of SMEO. Sociedad Mexicana de Oncología. 

    University teacher at Universidad Anahuac of Medicine since 2020.

     

     

  • Baca selengkapnya
Eksisi luas melanoma
$10,000 - $15,000
Lumpektomi
$10,000 - $12,000
Pneumonektomi
$35,000 - $37,000
Info